News
VRCA
5.69
+12.23%
0.62
Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)
TipRanks · 2d ago
Lake Street starts Verrica Pharmaceuticals with a Buy
TipRanks · 2d ago
Verrica Pharmaceuticals initiated with a Buy at Lake Street
TipRanks · 2d ago
Weekly Report: what happened at VRCA last week (0817-0821)?
Weekly Report · 5d ago
Verrica Pharmaceuticals Earnings Call: Growth Amid Losses
TipRanks · 08/22 00:26
Verrica Pharma Gains: What Is The Buzz?
NASDAQ · 08/19 15:23
Verrica’s Leadership Makes Bold Insider Bet on the Company’s Future
TipRanks · 08/19 02:01
Verrica Pharmaceuticals CEO buys $125.8K in common stock
TipRanks · 08/18 21:10
Weekly Report: what happened at VRCA last week (0810-0814)?
Weekly Report · 08/17 09:22
Weekly Report: what happened at VRCA last week (0803-0807)?
Weekly Report · 08/10 09:21
Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and 10x Genomics (TXG)
TipRanks · 08/07 18:00
Verrica: Buy Rating Reiterated on YCANTH Momentum, Pivotal Wart Program Progress, and Strengthened Balance Sheet; $12 Price Target Maintained
TipRanks · 08/07 10:55
Stacy Ku Reiterates Buy on Verrica as Ycanth’s Strong Uptake and Wart Expansion Opportunity Support Long-Term Growth
TipRanks · 08/07 08:08
Verrica Pharmaceuticals Non-GAAP EPS of -$0.48 misses by $0.01, revenue of $5.9M beats by $0.16M
Seeking Alpha · 08/06 20:21
Press Release: Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
Dow Jones · 08/06 20:02
Weekly Report: what happened at VRCA last week (0727-0731)?
Weekly Report · 08/03 09:21
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 07/28 21:06
Weekly Report: what happened at VRCA last week (0720-0724)?
Weekly Report · 07/27 09:22
Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones
Benzinga · 07/21 12:07
Weekly Report: what happened at VRCA last week (0713-0717)?
Weekly Report · 07/20 09:21
More
Webull provides a variety of real-time VRCA stock news. You can receive the latest news about Verrica Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).